Everolimus Combined With Gefitinib in Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I/II Results and Signaling Pathway Implications

BACKGROUND: The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in PTEN-null tumors, thus we tested the combination of mTOR inhibition (everolimus) and EGFR inhibition (gefitinib) in castration-resistant prostate c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Rathkopf, Dana E., Larson, Steven M., Anand, Aseem, Morris, Michael J., Slovin, Susan F., Shaffer, David R., Heller, Glenn, Carver, Brett, Rosen, Neal, Scher, Howard I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4618268/
https://ncbi.nlm.nih.gov/pubmed/26178426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29578
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados